Determination of prostatic fluid citrate concentration using peroxidase-like activity of a peroxotitanium complex

• Published in: Analytical biochemistry 2023-07, Vol.672, p.115152-115152, Article 115152
• Main Authors: Yun, Kyong-Il, Pak, Un-Gyong, Han, Tong-Sul, Jo, Chol-Man, Sonu, Kyong-Su, Ri, Hyong-Gwan
• Format: Article
• Language: English
• Subjects: Biomarker; Body Fluids; Citrate; Citrates; Citric Acid; Early Detection of Cancer; Humans; Male; Peroxidases; Peroxotitanium complex; Prostate cancer; Prostatic Neoplasms - diagnosis
• ISSN: 0003-2697; 1096-0309
• DOI: 10.1016/j.ab.2023.115152

There have been developed many kinds of methods for detecting citrate in body fluids since citrate is very important physiologically and biochemically. In particular, determination of citrate concentration in prostatic or seminal fluid is useful in early diagnosis of prostate cancer. Recently, a peroxotitanium complex prepared from titanium tetrachloride and hydrogen peroxide has been shown to have peroxidase-like activity which is greatly inhibited by some hydroxyalkanoic acids. Hence, we established a method for determining citrate concentration in prostatic fluid using selective inhibition of citrate on the catalytic activity of the peroxotitanium complex. Inhibition rate of citrate against the catalysis of a peroxotitanium complex (PTC) is equal to the concentration ratio of citrate to PTC. [Display omitted] •The first application of the PTC's catalysis in analytical biochemistry.•Citrate equivalently binds to the PTC regardless of pH and H2O2.•H2PO4− is an inorganic interfering agent against the PTC's catalysis.•Prostatic fluid is suitable for citrate assay using the PTC's catalysis.